Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies.

Cancer medicine - 1 Sept 2021

Ding Lei, Dong Hui Yu, Zhou Tian Ren, Wang Yu Hao, Yan Tao, Li Jun Chen, Wang Zhong Yuan, Li Jie, Liang Chao

Abstract excerpt

With the widespread use of PD-1/PD-L1 monoclonal antibodies (mAbs) in the treatment of multiple malignant tumors, they were also gradually applied to advanced renal cell carcinoma (aRCC). Nowadays, multiple PD-1/PD-L1 mAbs, such as nivolumab, avelumab, and pembrolizumab, have achieved considerable efficacy in clinical trials. However, due to the primary, adaptive, and acquired resistance to these mAbs, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Drug Screening Assays, Antitumor

Share to Immune Checkpoint Inhibitors

Share to Kidney Neoplasms

Share to Programmed Cell Death 1 Receptor

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 34382349
DOI: 10.1002/cam4.4190
PMCID: PMC8446416

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies.PMID 34382349Read ↗

Treatment strategies for clear cell renal cell carcinoma: Past, present and futureSemantic proximity Read ↗

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.Semantic proximity Read ↗

Current updates and future perspectives on the management of renal cell carcinoma.Semantic proximity Read ↗

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.Semantic proximity Read ↗

Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsSemantic proximity Read ↗

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancerSemantic proximity Read ↗

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade.Semantic proximity Read ↗

Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-CarcinomaSemantic proximity Read ↗

Chemotherapy, Immunotherapy, and Surgery Should be Optimal Treatment Choices of Metastatic Sarcomatoid Renal Cell CarcinomaSemantic proximity Read ↗

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Semantic proximity Read ↗

Molecular basis for the treatment of renal cell carcinoma.Semantic proximity Read ↗

Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.